PharVision Advisers’s Hims & Hers Health HIMS Stock Holding History

PharVision Advisers’s Portfolio HIMS Stock Details HIMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,675	Closed	-$234K	–	381
2024 Q4	$234K	Buy	+9,675	New	+$240K	0.2%	243

Other funds holding HIMS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

PharVision Advisers's HIMS Position: Q1 2025 in Review

PharVision Advisers sold out of Hims & Hers Health (HIMS) in Q1 2025, closing a stake of 9,675 shares — an estimated $234K sold.

PharVision Advisers first reported a position in HIMS in Q4 2024 and held it in 1 quarter. The position peaked at $234K in Q4 2024. 429 funds tracked by Wall St. Rank hold HIMS as of Q1 2025.

PharVision Advisers reported no remaining Hims & Hers Health position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 9,675 Hims & Hers Health shares in Q1 2025, an estimated $234K.
PharVision Advisers first reported a position in Hims & Hers Health in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Hims & Hers Health position peaked at $234K in Q4 2024.
429 funds tracked by Wall St. Rank held Hims & Hers Health as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.